How mutation disrupts cell development, driving region-specific brain tumors
Scientists at St. Jude Children's Research Hospital have shown that specific brain cells respond differently to H3.3 K27M, a mutation in the histone H3.3 protein that drives many cases of diffuse midline glioma (DMG), depending on the cells' location in the developing brain. These findings help explain why DMG, a pediatric brain cancer commonly associated with this mutation, typically arises in…
Scientists at St. Jude Children's Research Hospital have uncovered how a specific genetic mutation, found in many brain tumors called diffuse midline glioma (DMG), influences the development of cells in different regions of the developing brain. This study, published in Nature Communications, reveals that the H3.3 K27M mutation, which perturbs the packaging and interpretation of DNA, behaves differently in OPCs (oligodendrocyte precursor cells) depending on where they are located within the brain.
The research focused on OPCs, the cells that develop into myelin-producing cells, to better understand why DMG typically arises in the brainstem and other midline regions of the brain, rather than in other parts. By comparing OPCs from regions where DMG is more common (the brainstem) to those from regions where it is less common (the telencephalon), researchers were able to track the cells' development and response to the mutation.
The results showed that H3.3 K27M alters the DNA packaging similarly across brain regions, but its downstream effects vary significantly. In OPCs from the brainstem, the mutation keeps cells in a more immature, actively dividing state for a longer period, compared to OPCs from other regions with the same mutation. This extended window of immaturity may explain why the brainstem is particularly susceptible to DMG.
Furthermore, the mutation disrupts signaling pathways that guide cell identity and development, with a stronger impact on developmental signaling in brainstem OPCs than in OPCs from other regions. This finding suggests potential targets for developing therapies tailored to this cancer, as well as highlighting the importance of understanding how pediatric cancers exploit normal developmental processes to drive tumor formation.
Senior author Suzanne Baker emphasized the significance of these findings, stating that understanding how pediatric cancers hijack normal developmental processes is crucial for improving treatments. The study's insights into regional differences in DMG localization may pave the way for more effective therapies for childhood brain cancers.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
